Celldex announces CDX-301 combination study 'positive' results Celldex Therapeutics announces "positive" results from a preclinical combination study of CDX-301 and Mozobil demonstrating that the combination of these agents significantly increases hematopoietic stem cell mobilization in mice. The data support future clinical development of CDX-301 and demonstrate a potent cell mobilization regimen combining CDX-301 and Mozobil, which may have significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation. The company said, "We plan to initiate a pilot clinical study evaluating CDX-301 alone and in combination with Mozobil in the transplant setting in early 2014 and look forward to seeing how this program progresses."
News For CLDX From The Last 14 Days
Check below for free stories on CLDX the last two weeks.